

The new Lupus Hub is now live

Wednesday 5 October, 2022

Related Sectors:

Medical & Pharmaceutical ::

Scan Me:



The Federation of Clinical Immunology Societies (FOCIS) and Scientific Education Support (SES) are thrilled to announce a strategic collaboration for healthcare professionals (HCPs) in the field of lupus. The aim of this collaboration is to achieve improved awareness, knowledge, and understanding of lupus.

Today, SES, along with FOCIS, the founding professional partner, has launched the new Lupus Hub. The Lupus Hub is an independent open-access educational website, dedicated to providing balanced, credible, and up-to-date medical education within the lupus space. The aim of the hub is to enhance knowledge on lupus through the multichannel dissemination of global advances related to classification, diagnosis, treatment, and management. To achieve this, the Lupus Hub will share new data, drug updates, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

Speaking at the launch, Betty Diamond, MD, Director of the Institute of Molecular Medicine at the Feinstein Institutes and member of the Lupus Hub Steering Committee, said:

"The Lupus Hub will provide up-to-date, evidence-based practice information to healthcare professionals to ensure quality care for patients with lupus. It represents an important new initiative for FOCIS, and an effort to ensure quality care for patients who are at the center of our research activities."

Mia Hill, IME Director at SES, said:

"We are excited to announce that the Lupus Hub is now live. Our shared vision with FOCIS is that every treatment team and researcher will have instant access to expert opinions and the latest evidence-based information on lupus to aid in treatment decisions and improve the lives of patients globally.

"FOCIS and SES believe that the Lupus Hub will become the solution for time-stretched HCPs to easily access up-to-date medical information to expedite learning and empower their treatment decisions. All hub content is guided by a steering committee of world-renowned experts, informed by patients, and endorsed by expert societies, in order to support HCPs worldwide.

"Activity such as this would not be possible without our supporters, GSK and AstraZeneca; therefore, we would like to take this opportunity to welcome GSK and AstraZeneca and thank them for their support. We welcome interest from all supporters that are keen to understand more about the Lupus Hub and how they can contribute to enhancing knowledge of lupus for HCPs around the world."

ENDS

All hub content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.

For more information on the Lupus Hub, please visit www.lupushub.com, and for more information on FOCIS, please visit <http://www.focisnet.org>.

For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com or Barry.Connolly@scientificeducationsupport.com.

NOTES TO EDITOR

About lupus

Systemic lupus erythematosus (SLE), commonly referred to as lupus, is a complex autoimmune disease commonly affecting the skin, joints/muscles, kidneys, and blood vessels. SLE is characterized by a relapsing remitting disease course, organ damage, and highly variable manifestations, which often overlap with other conditions, such as rheumatoid diseases, hematopoietic malignancies, and infections, which can lead to delayed diagnosis.

A common complication of SLE is lupus nephritis (LN), where the immune system targets the kidneys. LN significantly impacts morbidity and mortality and can result in chronic kidney disease and kidney failure. LN is also associated with cardiovascular morbidity and mortality, as well as adverse fertility and

pregnancy outcomes.

Early diagnosis and effective treatment are vital to achieve sustained immunologic responses and improved outcomes for patients with SLE and LN.

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our 'Know' education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support has a portfolio of successful websites supporting the advancement of medical education in the fields of hemato-oncology, rheumatology, and dermatology: [ALL Hub](#), [AML Hub](#), [GvHD Hub](#), [Lymphoma Hub](#), [MDS Hub](#), [MPN Hub](#), [Multiple Myeloma Hub](#), and [Psoriasis and Psoriatic Arthritis Hub](#).

About the Federation of Clinical Immunology Societies (FOCIS)

FOCIS exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases. FOCIS is a key forum where opinion leaders come together to chart the path to the next major breakthrough in disease therapy.

Through FOCIS, researchers and clinicians share knowledge across traditional disease borders, and identify commonalities between treatments and therapies that are life-changing for those impacted by immune-mediated diseases. [Visit the website for more information](#).

Company Contact:

Scientific Education Support

E. [Abbie.Gunn@scientificeducationsupport...](mailto:Abbie.Gunn@scientificeducationsupport.co.uk)

W. [https://www.scientificeducationsuppor...](https://www.scientificeducationsupport.co.uk)

View Online

Newsroom: Visit our Newsroom for all the latest stories:

<https://www.scientific-education-support.pressat.co.uk>